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Abstract
Background: Biologic predictors or biomarkers of survival in pulmonary fibrosis with a worse prognosis, more
specifically in idiopathic pulmonary fibrosis would help the clinician in deciding whether or not to treat since
treatment carries a potential risk for adverse events. These decisions are made easier if accurate and objective
measurements of the patients’ clinical status can predict the risk of progression to death.
Method: A literature review is given on different biomarkers of survival in interstitial lung disease, mainly in IPF,
since this disease has the worst prognosis.
Conclusion: Serum biomarkers, and markers measured by medical imaging as HRCT, pertechnegas, DTPA en FDG-
PET are not ready for clinical use to predict mortality in different forms of ILD. A baseline FVC, a change of FVC of
more than 10%, and change in 6MWD are clinically helpful predictors of survival.
Introduction
Interstitial lung diseases (ILD) [1] are a heterogeneous
group of lung diseases that comprise more than 200
clinical pathological entities. Although clinically the dif-
ferent ILD have rather similar presentations with
increasing shortness of breath, a restrictive lung func-
tion, impaired gas exchange and a widespread shadow-
ing on the chest radiograph, they comprise a very wide
spectrum of pathologies, clinical manifestations, and
outcomes. Approximately two-thirds of ILD cases have
no reported aetiology [2]. The remaining one-third is
associated with or defined by various environmental or
occupational factors including cigarette smoking, aspira-
tion, certain drugs and radiation therapy [3,4]. Despite
their acknowledged complexity, there is little evidence
about the best management of ILD. Morbidity of the
ILD themselves and adverse events of the available treat-
ments may be high, with potentially serious conse-
quences therefore for mismanagement. Improved
survival and cure from different forms of ILD are
dependent on a better understanding of the pathophy-
siology of the disease, its diagnostic accuracy in clinical
practice, and an analysis of possible biomarkers which
can guide the clinician in their treatment [5].
The clinical course of individual patients with ILD is
variable and can manifest long periods of stability, a
steady gradual decline, and/or periods of acute deteriora-
tion [6]. Some forms of ILD respond well to therapy,
others are insensitive to high doses of anti-inflammatory
drugs (e.g. dexamethasone) or immunosuppressive
agents. Lung transplantation is an option for some
patients, but many patients are too old or die on the
waiting list [7]. One potential reason for the high mortal-
ity on the lung transplant waiting list is the variable
course of the disease, which makes it difficult to predict
outcome. Consequently, the identification of predictors
of survival is critical for physicians and patients [8].
In the search for an effective therapy, biologic predic-
tors of survival in pulmonary fibrosis with a worse prog-
nosis, more specifically in IPF, have been extensively
studied in the last 10 years. These surrogate endpoints
for survival are so-called biologic markers or biomarkers.
They can be subdivided into those markers measured in
serum, those measured by lung function testing and
those by imaging techniques. Before discussing the differ-
ent results of the studies performed on predictors of sur-
vival, an introduction about what a biomarker is, is given.
What is a biomarker ?
“A biomarker indicates a change in expression or state
of a biologic measurement (e.g. concentration of a
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protein in serum, lung function measurement, amount
of ground glass on HRCT, ...) at a given time point that
correlates with the risk or progression of a disease, or
with the susceptibility of the disease to a given treat-
ment at a future time point [9]“. Once a proposed bio-
marker has been validated, it is used to diagnose disease
risk, presence of disease in an individual, or to tailor
treatments for the disease in an individual [9]. In evalu-
ating potential drug therapies, a biomarker may be used
as a surrogate for a natural endpoint such as survival or
irreversible morbidity [9]. If a treatment alters the bio-
marker, which has a direct connection to improved
health, the biomarker serves as a surrogate endpoint for
evaluating clinical benefit [9].
Use of such a biomarker as surrogate endpoint to
assess a clinical endpoint (e.g. survival) has potential dis-
advantages. Biomarkers can be difficult to validate and
require different levels of validation depending on their
intended use [10]. If a biomarker is used to measure the
success of a therapeutic intervention, the biomarker
should reflect a direct effect of that intervention [10].
In summary, 4 pitfalls are present during the valida-
tion process of a biomarker as a diagnostic test [11]: (1)
presence of a “spectrum bias”, i.e. the study population
on which the biomarker was validated has a different
clinical spectrum (e.g. more advanced disease) than the
population in whom the test has to be applied; (2) pre-
sence of a “selection bias”, i.e. the test results of the vali-
dation study are related to test results (e.g. FVC < 90%);
(3) presence of an “observer bias”, i.e. observer (e.g.
pathologist) is influenced by prior knowledge; and (4)
presence of an “observer variability”, i.e. the presence of
variability in the interpretation of the results by the
same observer (intra-observer variability) or by different
observers (inter-observer variability).
Serum biomarkers
At the end of the 1990s various serum markers were
tested for their use in ILD, more specifically in IPF.
Many markers have been studied and those with the
most promise are surfactant proteins A and D (SP-A
and SP-D), KL-6, and lactate dehydrogenase (LDH). In
2009 serum CC-chemokine ligand 18 (CCL-18) was pre-
sented as a potential biomarker in IPF [8]. Serum SP-A
and SP-D are hydrophilic surfactant proteins produced
and secreted by type II pneumocytes. Their concentra-
tion is elevated in certain inflammatory lung diseases,
including IPF [12]. Why the concentrations of these
proteins are elevated in these lung diseases is not pre-
cisely known. It is probably due to a combination of a
loss of integrity of the epithelial barrier caused by lung
injury and of an increased mass of type II cells due to
hyperplasia [12]. Three studies tried to validate the use
of these serum markers in an IPF population as a
predictor for survival. The study of Takahashi et al. [13]
concluded in a population of 52 IPF patients (mean fol-
low up time 11.4 months for the subjects who died,
more than 3 years for the survivors) that in the group of
survivors (n = 10) the concentrations of SP-A and SP-D
were within the normal range. In those subjects who
died, around 25% also had protein concentrations within
the normal range [13]. The second study by Greene
et al. validated the use of SP-A and D in a population of
142 IPF patients as a predictor of survival. They used a
Cox’s proportional hazards model and found that an
elevated concentration of SP-D (and not for SP-A) had
a 56% elevated increase in death after adjusting for age,
smoking status, TLC, FVC, FEV1, DLco and resting PA-a
O2 [12]. The third study was recently published by Kin-
der et al [14]. It was found in 82 IPF patients that each
increase of 49 ng/mL in baseline SP-A level was asso-
ciated with a 3.3 fold increased risk of mortality in the
first year after presentation. They observed no statisti-
cally significant association with serum SP-D and mor-
tality [14]. In conclusion SP-A and D are promising
biomarkers, but can not yet be used as a biomarkers for
survival. When reviewing the studies, large standard
deviations of the measured surfactant concentrations
were found. This questions the reproducibility of the
measurements.
In 1989, Kohno et al. discovered a compound named
KL-6, a mucin-like high-molecular weight glycoprotein,
which is expressed on type II alveolar pneumocytes [15].
Concentrations of KL-6 in serum and broncho-alveolar
lavage fluid are elevated in different forms of ILD [15].
However, an elevated concentration of KL-6 is not spe-
cific for alveolitis in ILD, as this is also seen in breast
cancer [16], non small cell lung cancer [17], colorectal
cancer [18] and pulmonary tuberculosis [19]. Yokoyama
et al. published a study of 14 IPF patients who received
a predefined therapy of a weekly pulse of high dose cor-
ticosteroids for at least 3 weeks. The concentration of
KL-6 was measured one week before and, 1 and 3 weeks
after start of treatment. They found that a decrease in
concentration of KL-6 was a good predictor of survival
(n = 8) [20]. Different studies have been published indi-
cating that the presence of alveolitis is correlated with
an elevated concentration of KL-6 [21-23]. However,
most of these studies have been performed with small
number of subjects and therefore use of KL-6 as a bio-
marker for prognosis or response to therapy in ILD still
needs to be validated with an unbiased and representa-
tive study population.
Some authors suggest that LDH is a potential marker
of disease activity and of response to therapy in different
forms of ILD [24-27]. Cytoplasmatic enzymes, like LDH,
when present in the extracellular space are indicators of
cell damage or cell death [25]. A case report of an IPF
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patient suggests a good correlation between level of
serum LDH and response to therapy [28]. In contrast
the study of Thomeer et al. found no correlation
between survival and concentration or change in con-
centration of serum LDH. Our results can, however, be
biased by the fact that an increase of LDH is also seen
with intake of azathioprine, a drug that was given to all
patients in this study. Serum LDH is a sensitive marker
for cell injury, but is a non specific test since the con-
centration is elevated in different circumstances of cell
injury caused by ischaemia, as by excess heat or cold,
starvation, dehydration, injury, exposure to bacterial tox-
ins, after ingestion of certain drugs, and from chemical
poisonings [25]. Consequently, serum LDH is difficult to
use as a valid biomarker of disease activity in ILD since
its concentration is defined by many factors.
CCL18 is a CC-chemokine produced by human mye-
loid cells [8]. CCL18 is known to trigger a biological
response in vitro in T cells, B cells, dentritic cells, hema-
topoietic progenitor cells, fibroblasts, and potentially, in
monocytes/macrophages but not in neutrophiles [29]. It
is constitutively expressed at high levels in lung and at
low levels in some lymphoid tissues such as lymph
nodes, thymus, and appendix [29]. Macrophages that are
activated in a specific way, produce CCL18 and play a
role in tissue repair processes such as wound healing
and fibrosis [8]. CCL18 regulates collagen production by
lung fibroblasts and is abundantly produced by alveolar
macrophages in patients with IPF [8,30,31]. Prasse et al.
set up a prospective study of 72 IPF patients, followed
during 24 months with a pulmonary function every 6
months, but without a standardised treatment. They
found that baseline serum CCL18 concentrations pre-
dicted change in TLC and FVC at the 6-month follow-
up. In the group with high serum CCL18 concentrations
a higher incidence of disease progression was seen. A
cut-off value of 150 ng/ml calculated by ROC analysis,
predicts mortality (sensitivity 83%; specificity 77%, area
under the curve 0.80), with a hazard proportional ratio
adjusted for age, sex, and baseline pulmonary function
data of 8.0 [8]. One may conclude from this single study
that CCL18 is the first biomarker that predicts mortality
in IPF in such a clear way. However the process of mea-
suring CCL18 concentration by ELISA has some pitfalls
and its reproducibility and internal validity are of con-
cern. Prasse et al. suggest that a standardization of the
entire procedure from drawing blood over freezing and
thawing to ELISA measurement is mandatory to over-
come this concern [8]. The findings of Prasse et al.
induce important questions regarding the pathogenesis
or the search for therapy of IPF. Is CCL18, that stimu-
lates lung fibroblasts to produce collagen, the key to a
potential new treatment in IPF [29]? Is the lack of an
animal model for lung fibrosis explained by the fact that
a rodent counterpart for human CCL18 does not exist
[29]? Further studies are needed to elucidate these ques-
tions, and more precisely to discover a CCL18 receptor,
which is still not found [29].
Physiologic parameters as biomarker
Pulmonary function
ILD are usually characterised by a restrictive lung func-
tion, i.e. a reduction in lung volumes with preserved Tif-
feneau index (or FEV1/FVC ratio) together with a
reduction in DLco. However, in early disease, lung
volumes and DLco may be within the normal range [4].
Furthermore, in sarcoidosis and in Histiocytosis X evi-
dence of airflow obstruction is also found in more than
a quarter to half the patients in some studies [4]. Lung
volumes may be relatively preserved in smokers with
IPF possibly due to coexisting emphysema although the
Tiffeneau index remains normal. This suggests that the
using a restrictive lung function as an exclusive diagnos-
tic biomarker for ILD is neither sensitive nor specific
enough [4].
Serial lung function testing is used to monitor the
clinical course of the disease [4]. VC and DLco are the
most used and the simplest indicators to measure
change in ILD [4]. There is, however, little agreement
about how frequently these lung function measurements
must be obtained in the follow up of the different forms
of ILD. This is partly because the clinical course of the
different ILD shows a wide variation, from acute alveoli-
tis due to amiodarone to chronic fibrosis by
scleroderma.
Different studies have addressed the question if lung
function variables can be used to predict survival. A
study of our group presented the survival rates between
the most common forms of ILD, with a mean survival
after 5 yrs of 91.6% in SARC, 84.1% in HP, 69.7% in
CTD, 35.4% in IPF, 85.5% in other IIP and 69.5% in
undefined forms of lung fibrosis [32]. A Cox regression
analysis shows that an age of less than 66 year, a diagno-
sis of an ILD that is not an IPF, a VC of more than 63%
predicted and a % macrophages of less than 63% in BALF
is indicative in this model of a lower mortality risk. DLco
was not found as an independent variable for survival.
The spinoff of the IFIGENIA trial aimed to quantify
the risk for mortality in 155 IPF patients after 4 years of
the date of inclusion in the IFIGENIA study [33]. The
study subjects were followed with measurements of VC,
TLC and DLco at baseline, month 6 and month 12 after
inclusion. A TLC > 62% predicted (HR 0.49; 95%CI
0.30-0.81) and a DLco > 43% (HR 0.37; 95%CI 0.23-0.61)
at baseline were found to influence rate of survival by a
Cox’s regression analysis. Changes in VC or DLco over 6
or 12 months were not found to be independent vari-
ables of survival.
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Martinez et al. analysed retrospectively data from the
placebo group (168 IPF patients with mild to moderate
disease) of a trial evaluating interferon gamma as treat-
ment for IPF [6,34]. At 12 week intervals DLco and VC
were measured over a median period of 76 weeks.
Twenty one percent died, of which IPF (89%) was the pri-
mary cause of death [6]. In patients with an IPF-related
death, 15 (47%) deaths were categorised as acute or
abrupt and 16 deaths (50%) were considered subacute.
For patients who survived to week 72, the mean percen-
tage predicted FVC decreased from 64.5% (SD 11.1%) to
61.0% (SD 14.1%). The mean percentage predicted
decreased from 37.8% (SD 11.1%) to 37.0% (SD 19.9%)
[6]. For patients who died during this trial, a general
trend toward a decrease in FVC and DLco was observed,
although significant intra-patient variability occurred
over time [6]. Martinez et al. concluded that the clinical
course of patients with mild to moderate IPF was charac-
terised by minimal physiologic deterioration as measured
by FVC and DLco over a period of 76 weeks [6].
Flaherty et al. examined retrospectively 80 patients
with IPF and 29 patients with NSIP [35]. They found
that in a multivariate Cox proportional hazards model
controlling for histopathologic diagnosis (UIP versus
NSIP), gender, smoking history, baseline FVC, and 6
month change in FVC, a decrease in FVC of more than
10% remained an independent risk factor for mortality
(HR 2.47; 95%CI 1.29-4.73) [35].
Various other investigators have also suggested that a
decreased FVC at baseline identifies patients at subse-
quent risk of mortality [36-40]. In addition, some sug-
gested that a decrease in FVC of 10% or more after 1
year predicts mortality in patients with IPF [41]. Spiro-
metric assessment is particularly valuable as its measure-
ment is standardised [43] and the variability in FVC is
well defined among normal subjects and patients with
pulmonary disease [42,43]. Despite these standards, a
variability in the FVC measurements of patients with IPF
over time is noted [44,45]. As a result, a wide variety of
thresholds for change in FVC is used, including changes
ranging from 10 to 15% in FVC [35,39,41,46-48].
Flaherty et al. demonstrated that the change in DLco
over 6 months of follow-up has limited prognostic value
and this measurement was not found to add indepen-
dent predictive value for mortality in IPF [35]. Although
standards are presented for its measurement [49,50], the
DLco varies to an even greater extent than FVC and
clinically significant changes are believed to be more
than 20% [35,41,46,47,51]. As such, a survival advantage
was noted by one group in patients with an improved or
unchanged DLco compared with those experiencing a
decrease of 20% or more after 1 year of therapy [35].
The question remains whether FVC and DLco are use-
ful as surrogate markers for survival in trials searching
for therapeutic strategy in IPF? This question is critical
since change from baseline to a specified time point of
these physiologic variables has been used either or both
as primary endpoint in the most recent therapeutic trials
in IPF [52].
The INSPIRE trial, the largest trial ever, included 1373
IPF patients, and concluded that no difference is seen in
survival between those treated with interferon gamma
and those with placebo [53]. Consistent with the find-
ings as described above, the INSPIRE investigators
noted negligible changes in mean values of FVC and
DLco during 77 weeks treatment with either interferon
gamma or placebo [53].
With the available evidence, it is difficult to conclude
that a decrease or a change over time in FVC or DLco
are valid biomarkers for survival, because the results of
above mentioned trials are confusing. Is survival itself
the only valid endpoint to be used in therapeutic trials?
IPF is a rare disease, and if investigators decide only to
use survival as primary endpoint, trials will be difficult
to set up and manage to a successful conclusion. Taking
the INSPIRE study as an example, the investigators cal-
culated at the onset of the trial that to have 90% statisti-
cal power to detect a treatment effect equivalent to a
50% reduction in 3-years, about 600 patients were
needed to achieve the targeted number of deaths within
the planned duration of the study (77 weeks). Two
interim analyses of this trial increased the number to
1200 patients. The economic and logistic efforts (world-
wide participation of 82 centres) to bring this to a suc-
cessful conclusion are huge. Efforts not every
investigator or pharmaceutical company can afford [54].
Six minute walking distance
Different studies have evaluated the correlation
between 6 minute walking distance (6 MWD) or
change in walking distance and survival [55-61]. Most
of these studies are characterised by small sample size,
and therefore yielded inconsistent results related to
survival. Only one study, recently presented as an
abstract, found in a post hoc analysis of the INSPIRE
trial of 822 IPF patients, that a 24 week change in 6
MWD was highly predictive to mortality: a 24 week
decrement of > 50 m was associated with a 4.3 fold
increase in one-year mortality, a decrement between
26-50 m an increase of 3.6 [62].
Biomarkers measured by medical imaging
Two types of medical imaging are discussed. HRCT and
nuclear imaging including imaging that measures the
alveolar capillary membrane permeability of the lung by
use of radioactive isotopes, pertechnegas and 99mTc-
diethylenetriamine pentacetate (DTPA), and positron
emission tomography (PET).
Thomeer et al. Respiratory Research 2010, 11:89
http://respiratory-research.com/content/11/1/89
Page 4 of 7
It is nowadays unthinkable not to use HRCT in the
diagnosis of ILD. The added value of HRCT depends
upon its ability to increase confidence of a specific diag-
nosis, to alter patient management and, if possible, to
influence outcome [4]. Research on the ability of HRCT
scans to differentiate between active and inactive disease
has been mainly confined to IPF and ILD associated
with systemic sclerosis [4]. There is evidence that a pre-
dominant ground glass pattern is more likely to repre-
sent active inflammatory disease and to respond to
appropriate therapy, particularly in fibrosing alveolitis,
EAA, and desquamative interstitial pneumonia [63-65].
It is still unproven that a ground glass pattern precedes
a reticular or honeycomb pattern, although this seems
likely [4]. Not all ground glass change indicates cellular
inflammation, however, as fine intralobular fibrosis may
be indistinguishable from a cellular infiltrate on HRCT
scans [64,66]. The association of a ground glass pattern
with traction bronchiectasis or bronchiolectasis is likely
to indicate some associated fibrosis, whereas ground
glass change without traction bronchiectasis usually
indicates active inflammation [66]. Reticular and honey-
comb patterns on HRCT scans correlate well with histo-
logical evidence of fibrosis [67,68].
Can HRCT predict response to therapy in IPF? Gay
et al. set up a study with 38 biopsy proven IPF patients.
The study patients received 1 mg/kg prednisone daily
during 3 months. The HRCT before treatment was
scored (score from 0 to 5 for each lobe) for ground
glass and fibrosis by 4 radiologists independently. They
demonstrated that a fibrosis score of 2 or more has a
80% sensitivity and 85% specificity in predicting survival
[69]. From this study it is not clear how many drop outs
were present during the survival follow up and how
long the time of follow up was, two factors that can
induce a possible bias in their results. A spin off trial of
the IFIGENIA study used the same scoring method pro-
posed by Gay et al. The HRCT was scored before start
of a predefined treatment of azathioprine and predni-
sone and at 6 and 12 months of treatment. The HRCT
scores for fibrosis and ground glass were assessed by 3
radiologists independently. In this study 155 IPF patients
had a median follow up of 2.5 yrs (SD 1.8). Only the
fibrosis score at baseline was predictive for survival (HR
1.58 95% CI 1.15-2.17), whereas ground glass score or
changes in ground glass score or fibrosis score over 6
and 12 months were not predictive for survival. A
HRCT fibrosis score of more than 2 had a relative risk
for death of 2.31 (95%CI 1.40-3.80). However the area
under the curve for the fibrosis score was only 0.61
(95%CI 0.52-0.70), which means that the score had only
a moderate to low sensitivity and specificity for survival.
The ILD are characterised by an acute or chronic
inflammation of the interstitium, also called the alveolar
capillary membrane [70]. A possible way to measure the
alveolar capillary membrane permeability is by radio-
nuclide aerosol lung imaging. The rate of the clearance
of the aerosol is inversely related to the integrity of the
alveolar capillary barrier [71-73]. Pertechnegas and
DTPA have been studied as disease activity measure in
different forms of interstial lung diseases, but, as far as
we known, no studies has correlated rate of lung clear-
ance with survival [73,74].
Positron emission tomography (PET) imaging has
recently emerged on the scene of biomarkers of ILD.
A number of studies has suggested that 18F-FDG PET
imaging may serve as a sensitive tool for the evaluation
of disease activity in sarcoidosis, with higher sensitivity
and interobserver agreement compared to the classical
Gallium scintigraphy [75-77]. The potential value of 18F-
FDG PET as a biomarker for disease activity in other
ILD is less clear. In IPF the magnitude of 18F-FDG
uptake in the lungs is usually low. As 18F-FDG is
thought to assess the inflammatory burden and not the
fibrosis, the finding of relatively low SUV in IPF can be
regarded as confirmative for the concept that inflamma-
tion does not play a major role in the pathogenesis of
this disease. No studies are present that correlates rate
of 18F-FDG uptake with survival in specific forms of
interstitial lung diseases.
Conclusion
Interstitial lung diseases are a diverse and complex col-
lection of parenchymal lung diseases that vary widely
in aetiology, histopathology, clinical radiological pre-
sentation, and clinical course [78]. There is an urgent
need for biomarkers or markers of disease activity that
would help the clinician in deciding whether or not to
treat since treatment carries a potential risk for
adverse events. These decisions are made easier if
accurate and objective measurements of the patients’
clinical status can predict the risk of progression to
death. Serum biomarkers, and markers measured by
medical imaging as HRCT, pertechnegas, DTPA en
FDG-PET are not ready for clinical use to predict mor-
tality in different forms of ILD. A baseline FVC, a
change of FVC of more than 10%, and a decrement of
more than 25 m in 6 MWD are predictors of survival.
Measurements of FVC and 6 MWD are clinically easy
to do, results are measured in no time and pose mini-
mal effort for the patient.
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